Cytokinetics Q3 basic EPS USD -1.37

CYTK•2026-11-04

Cytokinetics reported Q3 basic EPS of USD -1.37, operating income of USD -167.088 million, net income of USD -190.069 million and operating expenses of USD 214.645 million.

1. Quarterly results

Cytokinetics reported Q3 basic EPS of USD -1.37. Operating income was USD -167.088 million, net income was USD -190.069 million and operating expenses were USD 214.645 million.

Cytokinetics Q3 basic EPS USD -1.37

1. Quarterly results

Related News

MKS Q3 revenue beats estimates on semiconductor growth; lifts Q4 revenue outlook

Riley Exploration Permian Q3 revenue jumps on higher output

Royal Gold Q3 revenue rises 84% on higher metal prices

Energy Recovery Q3 revenue misses estimates as Iran war weighs

WaterBridge Q3 2026 net income totals $13.3 million; revenue rises 17% to $240.2 million